Skip to content
mapperlab
← Dashboard
Stock

ANVS

Annovis Bio, Inc.
Latest close $2.052 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
2
27 funds tracked
Ever held
4
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

Nov 14, 2024May 14, 2025Aug 14, 2025May 14, 2026
Now
2

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Two Sigma Investments re-entered$2.73$2.05-25%
Renaissance Technologies re-entered$1.69$2.05+21%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Citadel Advisors 2× in & out→ $2.38-12%
D.E. Shaw 2× in & out→ $2.72+61%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Annovis Bio, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
1
Filings · last 90d
2
Total on file
80
Recent SEC buffer
Most recent
May 21, 2026

30d / 90d windows measured from May 21, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 80 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Annovis Bio, Inc.

Annual figures sourced directly from Annovis Bio, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$0
FY2025
Net income
-$28.85M
FY2025-17% YoY
EPS (diluted)
$-1.40
FY2025+39% YoY
Free cash flow(?)
-$25.62M
FY2025-17% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Annovis Bio, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Renaissance TechnologiesQ2 2026open$2.13$2.05-4%
Two Sigma InvestmentsQ1 2026open$2.38$2.05-14%
Citadel AdvisorsQ3 2025Q1 2026$2.72$2.38-12%
D.E. ShawQ2 2025Q3 2025$1.69$2.72+61%
Renaissance TechnologiesQ2 2025Q3 2025$1.69$2.70+60%
Two Sigma InvestmentsQ1 2025Q3 2025$2.73$2.72-0%
Citadel AdvisorsQ4 2024Q2 2025$6.97$1.69-76%
D.E. ShawQ4 2024Q1 2025$6.97$2.73-61%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.